Research & Development
Avingtrans subsidiary Adaptix secures FDA clearance for 3D orthopaedic imaging system
10 November 2025 - Avingtrans plc (AIM: AVG), a designer and manufacturer of critical systems for the energy, medical and industrial sectors, announced on Monday that its subsidiary Adaptix Limited ha...
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL
10 November 2025 - Biotechnology company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) announced on Monday that it has received FDA clearance to proceed with its confirmatory Phase 3 TELLOMAK ...
AN2 Therapeutics partners with GSK to develop boron-based TB therapies; Secures Gates Foundation funding
10 November 2025 - Biopharmaceutical company AN2 Therapeutics Inc (Nasdaq: ANTX) revealed on Monday that it has entered into a research collaboration with biopharmaceutical firm GSK to advance boron-b...
Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests
10 November 2025 - Cancer screening and diagnostic tests provider Exact Sciences Corp (NASDAQ: EXAS) on Monday announced the expiration of the Hart-Scott-Rodino Antitrust Act waiting period for its pr...
Boehringer Ingelheim receives Commissioner's National Priority Voucher for HERNEXEOS (zongertinib tablets)
10 November 2025 - Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zonge...
Sanofi and Regeneron's Dupixent meets all endpoints in pivotal AFRS study; sBLA accepted for FDA priority review
7 November 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Friday announced positive results from the phase 3 LIBERTY-AFRS-AIMS study evaluating Dupixent (dupilumab) ...